Tumor Immunology

肿瘤免疫学项目区由34名成员组成，横跨加州大学洛杉矶分校的14个部门。 在过去的竞争周期中，该项目的研究人员撰写了536篇论文，其中271篇(51%) 是方案间的，119个(22%)是方案内的。175篇(33%)发表在高影响力的期刊上。 此计划区域的22个成员使用了8个共享资源中的8个，这些资源目前由 JCCC。在本供资年度，经同行审查的资金总额为2000万美元，其中包括360万美元 来自国家癌症研究所。与其他计划领域一样，JCCC培养了许多互动的 支持TL计划领域研究人员的活动和许多共享资源。在.期间 目前的赠款周期，JCCC以CCSG发展基金的形式提供的资金，机构支助和 给TL计划地区的慈善捐赠总额为1,750,995美元。这些基金支持跨学科拨款， 种子赠款，招聘/保留，计划领域领导支持，使用新兴共享的资金 资源和受训人员。项目区成员中有17人接受了JCCC的资助。 肿瘤免疫规划领域的主要目标是：(1)提供最佳互动环境 提高对肿瘤免疫学的认识；(2)开发以免疫为基础的临床新疗法。 这个项目将基础科学家和翻译科学家聚集在一起，进入了一个催生了小说的环境 研究人员发起的针对黑色素瘤、肝细胞癌和脑癌的免疫治疗临床试验。 肿瘤免疫学协会与JCCC计划的其他领域相互作用，促进免疫治疗的临床试验 在肺癌(胸科肿瘤学)和肾癌(泌尿生殖系统肿瘤学)。的主要领域 已建立的方案内和方案间研究包括：(1)树突状细胞(DC)疫苗的测试 癌症治疗途径；(2)T淋巴细胞及其前体细胞与T细胞受体的基因工程 (3)肿瘤抗原的非侵入性体内成像 T细胞在体内的分布与肿瘤靶向；(4)炎症与肿瘤的关系； (5)抗体融合蛋白在癌症治疗中的应用；(6)致敏的药理学策略 对癌细胞进行免疫治疗。高度协作的方案内研究的新兴领域包括 与胸科肿瘤学和女性癌症计划领域广泛互动，共同开发新的 肿瘤免疫学方法及其在T细胞老化、T调节细胞基础研究中的应用 生物学、免疫转录调节因子和维生素D生物学到肿瘤免疫学模型。最基本的 肿瘤免疫学项目领域内的转译研究几乎使用了JCCC的所有基础设施 并为其正在进行的研究努力共享资源。流式细胞仪共享资源已被 计划范围内的大多数(如果不是全部)研究项目都需要。小动物影像分享 资源使T细胞成像方面的成功项目成为可能，这些项目现在正在 从临床前模型带给患者。

The Tumor Immunology Program Area is composed of 34 members, spanning 14 Departments within UCLA. In the past competing cycle, investigators from this Program authored 536 publications, of which 271 (51%) were inter-programmatic and 119 (22%) intra-programmatic. 175 (33%) were placed in high-impact journals. 22 members of this Program Area used 8 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled $20M in total costs, including $3.6M from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the Tl Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the Tl Program Area total $1,750,995. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Seventeen of the Program Area Members were the recipients of JCCC support. The Tumor Immunology Program Area has as its main goals: (1) to provide an optimal interactive environment to enhance the understanding of tumor immunology and (2) to develop novel immune-based clinical therapies. This program brings basic and translational scientists together into an environment that has spawned novel investigator-initiated immunotherapy clinical trials for melanoma, hepatocellular carcinoma, and brain cancers. The Tumor Immunology PA interacts with other JCCC Program Areas to facilitate immunotherapy clinical trials in lung cancer (Thoracic Oncology) and renal cell carcinoma (Genitourinary Oncology). The main areas of established intra- and inter-programmatic research include: (1) testing of dendritic cell (DC)-based vaccine approaches for cancer; (2) genetic engineering of T-lymphocytes and their precursors with T-cell receptors (TCR) to engineer a cancer-directed immune system; (3) non-invasive in vivo imaging of tumor antigenspecific T-cell in vivo distribution and tumor targeting; (4) the relationship between inflammation and cancer; (5) the use of antibody fusion proteins for cancer therapy; and (6) pharmacological strategies to sensitize cancer cells to immunotherapy. Emerging areas of highly collaborative intra-programmatic research include a broad interaction with the Thoracic Oncology and Women's Cancers Program Areas to jointly develop novel tumor immunology approaches, and the application of basic research on T-cell aging, T- regulatory (Treg) cell biology, immune transcriptional regulators, and vitamin D biology to models of tumor immunology. The basic and translational research within the Tumor Immunology Program Area uses nearly all the JCCC infrastructure and Shared Resources for its ongoing research efforts. The Flow Cytometry Shared Resource has been required for most (if not all) research projects within the Program Area. The Small Animal Imaging Shared Resource has made possible the pursuit of successful projects in T-cell imaging, projects that are now being brought from preclinical models to patients.